

PATENT

Confirmation No. 9468

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Allen, Keith D.	Examiner:	Ton, Thaian N.
Serial No.:	09/903,393	Group Art Unit:	1632
Filed:	July 10, 2001	Docket No.:	R387/75658.021900
Title:	Transgenic Mice Containing Limulus Clotting Factor Protease-Like Gene Disruptions		

---

DECLARATION OF JOHN BURKE PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

6.20.05  
Considered  
TNT

Sir:

I, John E. Burke, residing at 16357 E. Berry Avenue, Centennial CO 80015, hereby declare:

1. I am currently, and have been since 1998, the Attorney of Record for the Applicant and Assignee, Deltagen, Inc. I am listed on the originally filed Power of Attorney for the present application. From December 1996 to December 1999, I was Of Counsel with the law firm of Pillsbury Madison & Sutro (currently Pillsbury Winthrop), where I represented Deltagen with respect to intellectual property matters, including patent matters relating to their transgenic mouse program. From December 1999 until December 2001, I served as Deltagen's Vice President of Intellectual Property, where I supervised Deltagen's internal patent department. All of the applications, including the present application, covering the 750 lines of mice in DeltaBase were drafted by Deltagen's patent department. From December 2001 until April 2003, I served as Deltagen's Senior Vice President and General Counsel. From April 2003 through April 2005, I was a partner with the Denver office of Merchant & Gould, where I continued to represent Deltagen with regard to intellectual matters, including patent matters. I am presently employed as a Shareholder with the Denver office of the law firm of Greenberg Traurig, where I am



S/N 10/180,949

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Keith D. Allen	Examiner:	Hama, Joanne
Serial No.:	10/180,949	Group Art Unit:	1632
Filed:	June 25, 2002	Docket No.:	R387/75658.021900
Title:	Transgenic Mice Containing Limulus Clotting Factor Protease-Like Gene Disruptions		

**CERTIFICATE UNDER 37 CFR 1.10**

'Express Mail' mailing label number: ED888667195US  
Date of Deposit: May 19, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By:   
Name: Mary C. Nader

DECLARATION OF ROBERT DRISCOLL PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Robert Driscoll, residing at 23 Chicory Lanc, San Carlos, CA 94070, hereby declare:

1. I am presently employed as Vice President of Intellectual Property & Legal Affairs at Assignee, Deltagen, Inc., in San Carlos, CA. I have also previously served as the Company's Senior Director of Intellectual Property, in which position I managed and oversaw the Company's intellectual property portfolio, including the Company's patent filings. I possess a Ph.D in Chemistry, received from the California Institute of Technology. I also possess a J.D., received from Loyola Law School, Los Angeles. I am a registered patent attorney (Reg. No. 47,536).

2. I am familiar with the above-cited application. I am familiar with the Office Action mailed December 15, 2004. I am aware that the Examiner has rejected the claims, in

6.20.05  
Considered  
TNT